One Case of Drug Treatment and Pharmaceutical Care in Patients with HIT after Coronary Artery Bypass Grafting

doi:10.19803/j.1672-8629.2021.03.17

Abstract

Abstract: Objective To investigate the formulation and pharmaceutical care of a case of heparin- induced thrombocytopenia after coronary artery bypass grafting Methods The related literature were searched in recent years, the correlation evaluation of adverse drug reaction was carried out in combination with this case to assist clinicians to formulate individualized treatment plans, including the selection of anticoagulant drugs, the intervention of antibacterial drug use and the dose adjustment of warfarin sodium after discharge, and to give the patients the whole course of pharmaceutical care. Results The patient was discharged from hospital stably, platelet returned to normal, the international normalized ratio reached the standard, and no obvious embolism and bleeding were found during hospitalization. Conclusion Clinical pharmacists assist doctors to formulate and optimize the whole course treatment plan and pharmaceutical care to ensure the safety, effectiveness and economy of drug use.

Key words: heparin, coronary artery bypass grafting, heparin-induced thrombocytopenia, pharmacy care, adverse drug reaction

CLC Number:

R944.11

ZHANG Yongna, ZHANG Yanjiao, ZHAO Li, HAN Yongxin. One Case of Drug Treatment and Pharmaceutical Care in Patients with HIT after Coronary Artery Bypass Grafting[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 284-288.

References

[1] Ge HY, Ding N.Pharmaceutical care and literature review of type Ⅱ thrombocytopenia induced by anticoagulant therapy on a patient with acute pulmonary embolism[J]. Journal of Pharmaceutical Practice(药学实践杂志), 2019, 37(3): 279-282.
[2] Ren J, Zhai ZG, Men JL.Evidence-based progress in clinical diagnosis and treatment of heparin-induced thrombopenia[J].Natl Med J China(中华医学杂志), 2017, 97(46): 3667-3670.
[3] Salter BS,Weiner MM,Trinh MA, et al.Heparin-induced thrombocytopenia: a comp- rehensive clinical review[J].J Am Coll Cardiol, 2016, 67(21): 2519-2532.
[4] Prince M, Wenham T.Heparin-induced thrombocytopenia[J].Postgrad Med J,2018,94(1114):453-457.
[5] Jiang Y, Shi GL, Zhang HJ.Pharmaceutical care on a patient with low molecular weight heparin calium-induced thromboeytopenia[J]. Herald of Medicine(医药导报), 2017, 36(4): 406-409.
[6] Wang XY, Jia D.Low molecular weight heparin induced thrombopenia: a case report and literature review[J]. Practical Pharmacy And Clinical Remedies(实用药物与临床), 2012, 15(10): 663-665.
[7] China Physicians Association Cardiovascular Physicians Branch Thrombus Prevention and Treatment Professional Committee. Consensus of Chinese experts on heparin-induced thrombopenia (2017)[J]. Natl Med J China(中华医学杂志), 2018, 98(6): 408-417.
[8] Bryant A, Low J, Austin S, et al.Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4Ts score and particle gel immunoassay[J]. Br J Haematol, 2008, 143( 5): 721-726.
[9] Shi XB, Hu DY.Beware of heparin-induced thrombocytopenia[J].Clinical Focus(临床荟萃), 2008, 23(8): 533-536.
[10] Shen YJ, Yang YJ.Diagnosis and treatment of thrombopenia induced by heparin[J].Chin J Cardiol(中华心血管病杂志), 2009,37(4):381-384.
[11] Linkins L A, Dans A L, Moores L K, et al.Treatment and prevention of heparin-induced thrombocytopenia[J]. Chest, 2012, 141(Suppl): S495-S530.
[12] Saugel B, Phillip V, Moessmer G, et al.Argatroban therapy for heparin-induced thrombocy- topenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study[J]. Crit Care, 2010, 14(3): 90-97.
[13] Zhang Q, Xu BY, Li WY, et al.Analysis of clinical pharmacist participating in one heparin-induced severe thrombocytopenia case after percutaneous coronary intervention[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2018, 22(4): 785-788.
[14] Zheng SF, Hu YF.Pharmaceutical care for anticoagulant therapy in a patient with repeating deep venous thrombosis[J]. China Pharmacy(中国药房), 2010, 21(42): 4029-4031.
[15] Chen AN, Zhu Z, Fan GR, et al.Progress in the study of heparin-induced thrombopenia[J]. Pharm J Chin PLA(解放军药学学报), 2018, 34(5): 445-450.
[16] Cardiovascular Science Branch of the Chinese Medical Association, Professional Committee of Cardiovascular and Cerebrovascular Diseases of Chinese Gerontology Society. Chinese expert consensus on warfarin anticoagulant therapy[J]. Chinese Journal of Internal Medicine(中华内科杂志), 2013, 52(1): 1-42.
[17] Zhang QX, Zhao SM, Yan SY.Analysis of rational use of warfarin in elderly patients based on a patient with pulmonary embolism who died of intracranial hemorrhage with substandard INR[J]. of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(2): 82-86.
[18] Vascular surgery section of Chinese Medical Association Surgical credits Association. Guide for the diagnosis and treatment of deep venous thrombosis[J]. Chinese Journal of General surgery(中华普通外科杂志), 2017, 32(9): 807-809.
[19] Tang FC.Importance and the related Issues of pharmaceutical care for application of warfarin in patients with mechanical valve replacement[J]. China Pharmacy(中国药房), 2009,20(35): 2791-2792.
[20] Zhu JP, Zhao R.Influence factors for the pharmacodynamics of warfarin[J]. Clinical Medication Journal(临床药物治疗杂志), 2009, 7(3): 55-58.
[21] Du LP, Ren S, Du XL, et al.Thrombocytopenia and acute renal failure caused by catheter-directed thrombolysis (CDT) and anticoagulant therapy: a case report[J]. Clinical Medication Journal(临床药物治疗杂志), 2017, 15(9): 80-82.
[22] Kang M, Alahmadi M, Sawh S, et al.Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study[J]. Blood, 2015, 125(6): 924-929.
[23] Greinacher A.Heparin-induced thrombocytopenia[J]. N Engl J Med,2015, 373(3):252-261.
[24] Greinacher A, Warkentin TE.Recognition, treatment and prevention of heaprin-induced thrombocytopenia: review and update[J]. Thromb Res, 2006, 118(2):165-176.